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Procalcitonin (PCT) is a useful bacterial infection biomarker with the potential for guiding 
antibiotic therapy. We evaluated the concordance of three automated PCT immunoassays: 
Kryptor (BRAHMS GmbH, Hennigsdorf, Germany), Atellica IM 1600 (Siemens Healthcare 
Diagnostics, Munich, Germany), and Cobas e801 (Roche Diagnostics, Mannheim, Ger-
many). In 119 serum samples with a PCT concentration <5.00 μg/L, Kryptor (reference 
assay) was compared with the other two immunoassays by Spearman’s rank correlation, 
regression analysis, and concordance at two antibiotic stewardship medical decision 
points: 0.25 and 0.50 μg/L. The Atellica IM 1600 and Cobas e801 results showed high 
correlations with those of Kryptor, with correlation coefficient (ρ) values of 0.97 and 0.99, 
respectively. However, negative biases were observed in both immunoassays (slope/y-in-
tercept: 0.75/–0.00 for Atellica IM 1600; 0.88/–0.01 for Cobas e801). Atellica IM 1600 
and Cobas e801 demonstrated excellent concordance with Kryptor at both medical deci-
sion points, with linearly weighted κ values of 0.90 and 0.92, respectively, despite discrep-
ancies, which were more prominent at the 0.25 μg/L medical decision point. Based on 
these biases and discrepancies, the alternate use of different PCT immunoassays in re-
peat examinations is inadvisable. Standardization is required before comparing the results 
of different PCT immunoassays.
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Procalcitonin (PCT) is a useful biomarker of bacterial infection 
and its resolution [1-3]. Repeated PCT concentration assess-
ment can be used to monitor the therapeutic response to guide 
medical decisions on early discontinuation of antibiotics and 
support personalized antibiotic management [2, 3]. Multiple 
studies have shown that PCT-guided antibiotic initiation and dis-
continuation can shorten the duration of antibiotic treatment, 
which can in turn reduce the associated side effects and im-
prove clinical outcomes [4-7]. Recently, two medical decision 
points have been suggested for PCT-guided antibiotic steward-
ship: 0.25 and 0.50 μg/L for non-intensive care unit (ICU) and 
ICU patients, respectively [2]. 
Sensitive and accurate determination of PCT concentration is 
required for its use as an antibiotic stewardship guide. Numer-
ous fully automated PCT immunoassays are available  [8]. How-
ever, because PCT reference material and methods are lacking, 
the comparability of these immunoassays is not guaranteed, ne-
cessitating comparative studies. Kryptor (BRAHMS GmbH, 
Hennigsdorf, Germany) was the first fully automated PCT im-
munoassay [9] and it was used in several clinically important 
studies to measure PCT concentrations [4, 6, 10]. Thus, most 
published comparative studies have used Kryptor as the refer-
ence method [11-20]. 
We examined whether PCT concentrations measured using 
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Atellica IM 1600 (Siemens Healthcare Diagnostics, Munich, 
Germany) and Cobas e801 (Roche Diagnostics, Mannheim, 
Germany) are equivalent to those measured using Kryptor in 
terms of PCT-guided antibiotic stewardship employing the medi-
cal decision points of 0.25 and 0.50 μg/L. To the best of our 
knowledge, this is the first study to evaluate Atellica IM 1600 in 
this regard. Our results would improve the understanding of 
how PCT concentrations can be influenced by different immu-
noassay principles employing the same BRAHMS PCT antibody.
For this comparison study, clinical serum samples were col-
lected from patients at Severance Hospital, Seoul, Korea, from 
March to April 2019. A routine PCT immunoassay was per-
formed using Cobas e601 upon collection. Immediately thereaf-
ter, 119 serum samples with a PCT concentration <5.00 μg/L 
were selected to increase the number of samples with PCT con-
centrations near the medical decision points, a strategy not ap-
Fig. 1. Comparative analysis of PCT concentrations measured by Atellica IM 1600, Cobas e801, and Kryptor by Passing–Bablok regression 
(left) and Bland–Altman plots (right). (A) Atellica IM 1600 vs. Kryptor (n=107). (B) Cobas e801 vs. Kryptor (n=113). (C) Atellica IM 1600 
vs. Cobas e801 (n=107). 
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plied previously. Selected samples were divided into three iden-
tical aliquots and stored at –70°C. All aliquots were thawed at 
20°C for an hour and immediately analyzed simultaneously for 
PCT concentration using three different immunoassays: Kryptor 
(BRAHMS PCT-sensitive KRYPTOR), Atellica IM 1600 (Atellica 
IM BRAHMS PCT), and Cobas e801 (Elecsys BRAHMS PCT). 
Detailed descriptions and technical data of these three immu-
noassays are summarized in Supplemental Data Table S1. This 
study was reviewed and the need for informed consent for re-
viewing medical records of the study population has been 
waived by the Institutional Review Board of Yonsei University of 
Medicine (4-2020-0013). 
The PCT concentrations measured by Atellica IM 1600 and 
Cobas e801 were compared with those measured by Kryptor 
(used as the reference assay). Spearman’s rank correlation co-
efficient (ρ) values, Passing-Bablok regression, Bland–Altman 
difference plots, and Cohen’s kappa coefficient (κ) were used 
for statistical analyses. The linearly weighted kappa coefficient 
across two PCT medical decision points, 0.25 and 0.50 μg/L, 
was used to assess overall concordance. All data were analyzed 
using Analyse-it (Analyse-it Software Ltd., Leeds, UK). The sta-
tistical significance threshold was set at P <0.05. 
All PCT concentrations measured by Kryptor were within the 
analytical measurement range of 0.03–4.63 μg/L (median: 0.30 
μg/L; interquartile range: 1.26). Atellica IM 1600 and Cobas 
e801 failed to detect PCT concentrations below the limit of de-
tection (Supplemental Data Table S1) in 12 and six samples, re-
spectively. These samples were excluded from the correlation 
and comparison analyses. Correlation analyses of the Atellica IM 
1600 and Cobas e801 PCT concentrations with the Kryptor PCT 
concentrations yielded strong ρ values of 0.97 and 0.99, re-
spectively (P <0.05 for both assays). However, both Atellica IM 
1600 and Cobas e801 showed a negative bias compared with 
Kryptor (Fig. 1A, B). The negative bias of Cobas e801 compared 
with Kryptor was more obvious at lower PCT concentrations, as 
the –0.01 negative constant bias was too high to be disregarded 
at lower PCT concentrations (e.g., a –0.01 constant bias only af-
fects approximately –1.0% at 1.00 μg/L vs –10.0% at 0.10 μg/
L). Atellica IM 1600 and Cobas e801 PCT concentrations 
showed a strong correlation (ρ=0.98; P <0.05) (Fig. 1C). 
Next, we investigated the influence of these systemic biases 
on the clinical interpretation of the PCT concentrations. To this 
end, the PCT concentrations of all 119 samples measured by all 
three immunoassays were classified into three categories based 
on the two medical decision points (0.25 and 0.50 μg/L). The 
overall concordance across the two PCT medical decision points 
(0.25 and 0.50 μg/L) of Atellica IM 1600 vs. Kryptor and Cobas 
e801 vs. Kryptor was 89.9 and 92.4%, respectively, with excel-
lent linearly weighted κ values (κ=0.90 for Atellica IM 1600; 
κ=0.92 for Cobas e801; Table 1). However, compared with 
Kryptor, Atellica IM 1600 underestimated the PCT concentration 
in 11 samples and overestimated it in one sample, whereas Co-
bas e801 underestimated the PCT concentration in nine sam-
ples (no overestimation; Table 2). Notably, the discordance did 
not surpass either medical decision point in the Atellica IM 
1,600 vs Kryptor or Cobas e801 vs Kryptor comparison, i.e., no 
sample was <0.25 µg/L by one method and >0.50 by the other 
(Table 2). Thirteen of the 119 samples (10.9%) measured by all 
three immunoassays were classified discordantly by at least one 
immunoassay; 10 at the 0.25 µg/L and three at the 0.50 μg/L 
medical decision point. 
These results indicate that despite excellent concordance, 
both Atellica IM 1600 and Cobas e801 still risk leading to pre-
mature cessation of antibiotics and treatment failure due to un-
derestimation of the PCT concentration compared with Kryptor. 
These discrepancies are more pronounced at the lower 0.25 
Table 1. Concordance and κ value analysis of PCT concentrations 
measured by Atellica IM 1600 and Cobas e801 compared with 
Kryptor (n=119)
Medical decision 
   point (µg/L)
Atellica IM 1600  
vs. Kryptor
Cobas e801  
vs. Kryptor
0.25* 91.6% (κ=0.83) 95.0% (κ=0.90)
0.50* 98.3% (κ=0.97) 97.5% (κ=0.95)




*One medical decision point was used to classify the PCT concentrations 
into two categories. †Two medical decision points were used simultaneously 
to classify the PCT concentrations into three categories.  
Abbreviation: PCT, procalcitonin.
Table 2. PCT concentration classification based on two medical de-
cision points, 0.25 and 0.50 μg/L (n=119)
Kryptor (µg/L)
<0.25 0.25–0.50 >0.50 
Atellica IM 1600 (µg/L) <0.25 54 9 -
0.25–0.50   1 3   2
>0.50 - - 50
Cobas e801 (µg/L) <0.25 55 6 -
0.25–0.50 - 6   3
>0.50 - - 49
Abbreviation: PCT, procalcitonin.
Cho HW, et al.
PCT assay concordance
422  www.annlabmed.org https://doi.org/10.3343/alm.2021.41.4.419
μg/L medical decision point. Thus, cautious interpretation of 
PCT concentrations measured by these immunoassays is 
needed, especially when they are near the lower 0.25 μg/L 
medical decision point. Atellica IM 1600 could not be compared 
with other instruments because of a lack of published data. The 
Cobas e801 vs Kryptor comparison results are largely consistent 
with previous data [19]. Although Lippi, et al. [18] did not place 
a 5.00 μg/L limit on sample collection, they reported a similar 
correlation (ρ: 0.99; P <0.05) compared with our data; however, 
they reported a lower negative bias (slope: 0.89; y-intercept: 
–0.01; mean percentage difference: –14.9% [95% CI: –18.5 to 
–11.2%]) when comparing Cobas e801 with Kryptor. In addi-
tion, they obtained similar concordance results, with more dis-
crepancies at the lower medical decision point of 0.25 μg/L than 
at 0.50 μg/L (96% at 0.25 μg/L and 99% at 0.50 μg/L) [19]. As 
all three immunoassays utilize the BRAHMS PCT monoclonal 
antibody, these discordances are likely to be related to the use 
of different calibrators by the manufacturers and/or lack of com-
mon reference materials, in addition to the innate differences in 
the immunoassay principles. 
Our study has some limitations. First, we did not include im-
munoassays employing antibodies other than BRAHMS PCT. 
However, the evaluated immunoassays showed biases and dis-
crepancies, supporting the necessity of reference materials and 
standardization methods [15, 17, 19, 21]. Second, duplicated 
sample measurements were not available because of volume 
limitations. Considering the number of samples used in this 
study, the possibility of random errors owing to the use of a sin-
gle replicate would have minimally affected the overall results. 
The strengths of this study are that it was the first to evaluate At-
ellica IM 1600 for PCT concentration measurement and that a 
large number of samples with concentrations close to the medi-
cal decision points were analyzed. 
In conclusion, this study demonstrated that the Atellica IM 
1600 and Cobas e801 immunoassays provide strongly corre-
lated and largely concordant PCT concentrations compared 
with Kryptor, despite the different assay principles. However, 
both immunoassays manifested modest negative bias com-
pared with Kryptor, which could, in some cases, result in discor-
dant medical decisions at the 0.25 and 0.50 μg/L medical deci-
sion points. Therefore, to successfully implement PCT-guided 
antibiotic stewardship, rigorous evaluation of immunoassay 
comparability is essential on the implementation of alternative 
PCT immunoassays. In addition, alternate use of different PCT 
immunoassays in repeat examinations should be avoided, be-
cause it can hamper the interpretation of PCT concentrations 
during longitudinal patient assessment. Furthermore, efforts 
should be made to develop and establish reference materials 
and methods for PCT concentration measurement, which would 
improve comparability and ultimately achieve standardization of 
the various PCT immunoassays.
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Supplemental Data Table S1. The three PCT immunoassays used in this study
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0.02 0.08 50 2.7–13.6 
Atellica IM 
1600







0.03 0.04 50 2.0–12.1 
Cobas e801 Elecsys BRAHMS 
PCT




0.02 0.06 100 1.0–7.9
*As specified by the manufacturers.       
Abbreviations: PCT, procalcitonin; LOD, limit of detection; LOQ, limit of quantification; AMR, analytical measurement range.
